Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

Microwave enhancement of CISH for HER2 oncogene.

Leong AS, Haffajee Z, Clarke M.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):88-93.

PMID:
17536314
[PubMed - indexed for MEDLINE]
2.

Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.

Francis GD, Jones MA, Beadle GF, Stein SR.

Diagn Mol Pathol. 2009 Jun;18(2):88-95. doi: 10.1097/PDM.0b013e31816f6374.

PMID:
19430296
[PubMed - indexed for MEDLINE]
3.

The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.

Pedersen M, Rasmussen BB.

Diagn Mol Pathol. 2009 Jun;18(2):96-102. doi: 10.1097/PDM.0b013e31817f5227.

PMID:
19430295
[PubMed - indexed for MEDLINE]
4.

A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.

Di Palma S, Collins N, Bilous M, Sapino A, Mottolese M, Kapranos N, Schmitt F, Isola J.

J Clin Pathol. 2008 Jun;61(6):757-60. doi: 10.1136/jcp.2007.053850. Epub 2008 Mar 6.

PMID:
18326010
[PubMed - indexed for MEDLINE]
5.

Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.

Nunes CB, Rocha RM, Reis-Filho JS, Lambros MB, Rocha GF, Sanches FS, Oliveira FN, Gobbi H.

J Clin Pathol. 2008 Aug;61(8):934-8. doi: 10.1136/jcp.2007.053892. Epub 2008 May 12.

PMID:
18474540
[PubMed - indexed for MEDLINE]
6.

Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.

Sińczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, Okoń K, Stachura J.

Pol J Pathol. 2007;58(1):41-50.

PMID:
17585541
[PubMed - indexed for MEDLINE]
7.

Microwaves for chromogenic in situ hybridization.

Leong AS, Haffajee Z.

Methods Mol Biol. 2011;724:79-89. doi: 10.1007/978-1-61779-055-3_5.

PMID:
21370007
[PubMed - indexed for MEDLINE]
8.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

PMID:
17922920
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?

Bartlett JM, Campbell FM, Mallon EA.

Am J Clin Pathol. 2008 Dec;130(6):920-6. doi: 10.1309/AJCPSDG53BEANCYE.

PMID:
19019769
[PubMed - indexed for MEDLINE]
Free Article
10.

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC.

Mod Pathol. 2008 Oct;21(10):1271-7. doi: 10.1038/modpathol.2008.83. Epub 2008 May 16.

PMID:
18487992
[PubMed - indexed for MEDLINE]
Free Article
11.

Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.

Gong Y, Sweet W, Duh YJ, Greenfield L, Fang Y, Zhao J, Tarco E, Symmans WF, Isola J, Sneige N.

Am J Clin Pathol. 2009 Apr;131(4):490-7. doi: 10.1309/AJCPI00TVGIGYXAA.

PMID:
19289584
[PubMed - indexed for MEDLINE]
Free Article
12.

PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.

Ni R, Mulligan AM, Have C, O'Malley FP.

Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):316-24.

PMID:
17721278
[PubMed - indexed for MEDLINE]
13.

Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.

Gong Y, Sweet W, Duh YJ, Greenfield L, Tarco E, Trivedi S, Symmans WF, Isola J, Sneige N.

Am J Clin Pathol. 2009 Aug;132(2):228-36. doi: 10.1309/AJCP4M2VUZCLDALN.

PMID:
19605817
[PubMed - indexed for MEDLINE]
Free Article
14.

Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations.

Chibon F, de Mascarel I, Sierankowski G, Brouste V, Bonnefoi H, Debled M, Mauriac L, MacGrogan G.

Mod Pathol. 2009 Mar;22(3):403-9. doi: 10.1038/modpathol.2008.195. Epub 2008 Dec 5.

PMID:
19060846
[PubMed - indexed for MEDLINE]
Free Article
15.

Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.

Cho EY, Choi YL, Han JJ, Kim KM, Oh YL.

Pathol Int. 2008 Jan;58(1):17-25.

PMID:
18067636
[PubMed - indexed for MEDLINE]
16.

Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.

Layfield LJ, Willmore-Payne C, Isom G, Holden JA.

Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):562-7. doi: 10.1097/PAI.0b013e318171923a.

PMID:
18948825
[PubMed - indexed for MEDLINE]
17.

Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases.

Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ.

Mod Pathol. 2008 Apr;21(4):363-8. doi: 10.1038/modpathol.3801021. Epub 2008 Feb 1.

PMID:
18246053
[PubMed - indexed for MEDLINE]
Free Article
18.

Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.

Drev P, Grazio SF, Bracko M.

Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):179-84. doi: 10.1097/PAI.0b013e31806875e1.

PMID:
18227723
[PubMed - indexed for MEDLINE]
19.

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma.

Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR.

Mod Pathol. 2007 Oct;20(10):1028-35. Epub 2007 Aug 3.

PMID:
17673923
[PubMed - indexed for MEDLINE]
Free Article
20.

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.

Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR.

Mod Pathol. 2009 Sep;22(9):1169-75. doi: 10.1038/modpathol.2009.78. Epub 2009 May 15.

PMID:
19448591
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk